Clinical trials recruiting for Sarcoma
48
Recruiting trials
47
US states with sites
12
Countries
12%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 13 |
| Texas | 11 |
| Massachusetts | 7 |
| Minnesota | 6 |
| Missouri | 6 |
| New York | 6 |
| Ohio | 6 |
| Florida | 5 |
| North Carolina | 5 |
| Pennsylvania | 5 |
| Arizona | 4 |
| Illinois | 4 |
Top cities
Houston, Texas 7Boston, Massachusetts 5St Louis, Missouri 5New York, New York 4Rochester, Minnesota 4Duarte, California 3Durham, North Carolina 3Grand Rapids, Michigan 3Lexington, Kentucky 3Omaha, Nebraska 3
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
- Analysis of Circulating Tumor Markers in Blood
- Biomarkers of Resiliency In Childhood Cancer Surgery
- BostonGene and Exigent Genomic INsight Study
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
- Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- DESTINY-PANTUMOUR04
- Development of Clinical and Biological Database
- Digital Peer Navigation for Adolescents and Young Adults With Cancer
- Distance-Based Exercise to Preserve Function and Prevent Disability
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Ex VIvo DEtermiNed Cancer Therapy
- FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
- HTL0039732 in Participants With Advanced Solid Tumours
- IDOV-Immune for Advanced Solid Tumors
- Integrated Cancer Repository for Cancer Research
- Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
- Ivonescimab in the Treatment of Multiple Advanced Tumors
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
- Navigation Intervention for Adolescent and Young Adult Cancer Survivors
- Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- PROMIS and Mobility Evaluation in Sarcoma Patients
- Phase II Trial of Lung Chemoemobolization
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
- Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
- START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
- Serial MRI Scans During Radiation Therapy
- Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
- Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
- Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Using QPOP to Predict Treatment for Sarcomas and Melanomas
- Video Education With Result Dependent dIsclosure
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Related conditions
Trials recruiting for Sarcoma often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Lung cancer 2180Colorectal cancer 1359Melanoma 487Pancreatic cancer 870Ovarian cancer 118Prostate cancer 1234Head and neck cancer 62Gastric cancer 91Esophageal cancer 65
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Sarcoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.